New and future therapies: Changes in the therapeutic armamentarium for SLE
Authors:
- 24 August 2023
- journal article
- research article
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 37 (4) , 101865
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of LupusPLOS ONE, 2014
- Regulation of type I interferon responsesNature Reviews Immunology, 2013
- Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double‐Blind, Phase III StudyArthritis & Rheumatism, 2013
- Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLELupus, 2012
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab studyArthritis & Rheumatism, 2012
- The PROMISE Study: A Phase 2b Multicenter Study of Voclosporin (ISA247) Versus Tacrolimus in De Novo Kidney TransplantationAmerican Journal of Transplantation, 2011
- Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2011
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis & Rheumatism, 2011
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialThe Lancet, 2011
- Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trialArthritis & Rheumatism, 2009